The use of left-sided Impella microaxial flow pumps has expanded rapidly for the management of cardiogenic shock, left ...
DANVERS, Mass.--(BUSINESS WIRE)--To mark the five year anniversary of the study by Stretch, et al., on cost and outcomes trends for short-term mechanical circulatory support, Abiomed announces a ...
Consistent evidence supports benefits of complete revascularization on LVEF, heart failure symptoms DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces the results of the Restore EF ...
The Impella XR sheath is a low-profile sheath that expands and recoils, allowing for small bore access and closure with the Impella 2.5 heart pump. It inserts at 10 French (Fr) and the flexible, ...
CLEVELAND — Forty-one-year-old Mark Kader is a husband, father of five, registered nurse, and associate clinical consultant for Abiomed, a medical device company. He's passionate about educating ...
MADRID, Aug. 31, 2025 /PRNewswire/ --Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously ...
Use of the Impella percutaneous left ventricular assist device (Abiomed) in acute MI complicated by cardiogenic shock (AMICS) in the United States increased nearly fivefold between 2012 and 2017, a ...
DANVERS, Mass.-Abiomed announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The expansion extends the duration of ...
A new national study finds that use of the Impella circulatory support device is associated with higher rates of death and major bleeding than a common alternative, especially among patients with ...
DANVERS, Mass. – Nov. 27, 2023 – Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).
isa Cardillo, then 36, and her husband were celebrating their 15th wedding anniversary and had just checked into a bed-and-breakfast when she felt a burning, stabbing pain in her chest. She was having ...
Several studies show that the use of percutaneous ventricular assist devices (PVADs), including Impella, is particularly cost-effective in cases of cardiogenic shock: Several studies, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback